Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.
Jackson DO, Byrd K, Vreeland TJ, Hale DF, Herbert GS, Greene JM, Schneble EJ, Berry JS, Trappey AF, Clifton GT, Hardin MO, Martin J, Elkas JC, Conrads TP, Darcy KM, Hamilton CA, Maxwell GL, Peoples GE.
Jackson DO, et al. Among authors: elkas jc.
Oncotarget. 2017 Feb 28;8(9):15912-15923. doi: 10.18632/oncotarget.13305.
Oncotarget. 2017.
PMID: 27852036
Free PMC article.
Clinical Trial.